These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20207610)

  • 1. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
    Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
    J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variability and trends in corticosteroid use by male United States participants with Duchenne muscular dystrophy in the Duchenne Registry.
    Cowen L; Mancini M; Martin A; Lucas A; Donovan JM
    BMC Neurol; 2019 May; 19(1):84. PubMed ID: 31046703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    Moxley RT; Ashwal S; Pandya S; Connolly A; Florence J; Mathews K; Baumbach L; McDonald C; Sussman M; Wade C; ;
    Neurology; 2005 Jan; 64(1):13-20. PubMed ID: 15642897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.
    Guglieri M; Bushby K; McDermott MP; Hart KA; Tawil R; Martens WB; Herr BE; McColl E; Speed C; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Willis T; Griggs RC; ; Straub V; van Ruiten H; Childs AM; Ciafaloni E; Shieh PB; Spinty S; Maggi L; Baranello G; Butterfield RJ; Horrocks IA; Roper H; Alhaswani Z; Flanigan KM; Kuntz NL; Manzur A; Darras BT; Kang PB; Morrison L; Krzesniak-Swinarska M; Mah JK; Mongini TE; Ricci F; von der Hagen M; Finkel RS; O'Reardon K; Wicklund M; Kumar A; McDonald CM; Han JJ; Joyce N; Henricson EK; Schara-Schmidt U; Gangfuss A; Wilichowski E; Barohn RJ; Statland JM; Campbell C; Vita G; Vita GL; Howard JF; Hughes I; McMillan HJ; Pegoraro E; Bello L; Burnette WB; Thangarajh M; Chang T
    JAMA; 2022 Apr; 327(15):1456-1468. PubMed ID: 35381069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.
    McAdam LC; Mayo AL; Alman BA; Biggar WD
    Acta Myol; 2012 May; 31(1):16-20. PubMed ID: 22655512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
    Wong BL; Christopher C
    J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
    King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
    Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics and emerging treatments for Duchenne and Becker muscular dystrophy.
    Wein N; Alfano L; Flanigan KM
    Pediatr Clin North Am; 2015 Jun; 62(3):723-42. PubMed ID: 26022172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk Factors for First Fractures Among Males With Duchenne or Becker Muscular Dystrophy.
    James KA; Cunniff C; Apkon SD; Mathews K; Lu Z; Holtzer C; Pandya S; Ciafaloni E; Miller L
    J Pediatr Orthop; 2015 Sep; 35(6):640-4. PubMed ID: 25379822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a New Self-Reporting Instrument Measuring Benefits and Side Effects of Corticosteroids in Duchenne Muscular Dystrophy: Report from a Pilot Study.
    Hendriksen RGF; Lionarons JM; Hendriksen JGM; Vles JSH; McAdam LC; Biggar WD
    J Neuromuscul Dis; 2017; 4(3):217-236. PubMed ID: 28800336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
    Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
    J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of vamorolone in Duchenne muscular dystrophy: An 18-month interim analysis of a non-randomized open-label extension study.
    Smith EC; Conklin LS; Hoffman EP; Clemens PR; Mah JK; Finkel RS; Guglieri M; Tulinius M; Nevo Y; Ryan MM; Webster R; Castro D; Kuntz NL; Kerchner L; Morgenroth LP; Arrieta A; Shimony M; Jaros M; Shale P; Gordish-Dressman H; Hagerty L; Dang UJ; Damsker JM; Schwartz BD; Mengle-Gaw LJ; McDonald CM;
    PLoS Med; 2020 Sep; 17(9):e1003222. PubMed ID: 32956407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
    Gloss D; Moxley RT; Ashwal S; Oskoui M
    Neurology; 2016 Feb; 86(5):465-72. PubMed ID: 26833937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect.
    Balaban B; Matthews DJ; Clayton GH; Carry T
    Am J Phys Med Rehabil; 2005 Nov; 84(11):843-50. PubMed ID: 16244521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vertebral fractures in boys with Duchenne muscular dystrophy.
    Bothwell JE; Gordon KE; Dooley JM; MacSween J; Cummings EA; Salisbury S
    Clin Pediatr (Phila); 2003 May; 42(4):353-6. PubMed ID: 12800730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols.
    Biggar WD; Politano L; Harris VA; Passamano L; Vajsar J; Alman B; Palladino A; Comi LI; Nigro G
    Neuromuscul Disord; 2004 Sep; 14(8-9):476-82. PubMed ID: 15336688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet.
    Butterfield RJ; Kirkov S; Conway KM; Johnson N; Matthews D; Phan H; Cai B; Paramsothy P; Thomas S; Feldkamp ML
    Muscle Nerve; 2022 Jul; 66(1):15-23. PubMed ID: 34994466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of steroid therapy for Duchenne muscular dystrophy in Japan.
    Goto M; Komaki H; Takeshita E; Abe Y; Ishiyama A; Sugai K; Sasaki M; Goto Y; Nonaka I
    Brain Dev; 2016 Oct; 38(9):785-91. PubMed ID: 27112384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.